Mutual Accupril Declaratory Judgment Case Versus Pfizer Thrown Out; Teva Exclusivity Intact
This article was originally published in The Pink Sheet Daily
Executive Summary
The court’s ruling means that Mutual cannot obtain a judgment that could potentially trigger Teva’s 180-day marketing exclusivity for the first generic version of Pfizer’s ACE inhibitor quinapril.
You may also be interested in...
Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.
‘Frontline’ Essential Workers, Persons 75 Years And Older Prioritized For Second Phase Of COVID Vaccination
Essential workers who cannot work remotely and have high levels of interaction with the public, and individuals ≥75 years old, should get vaccinated ahead of those 65-74 years old and those with comorbid conditions, CDC Advisory Committee on Immunization Practices recommends.
The Pfizer Effect: Moderna Tries To Escape Big Pharma’s Shadow At US FDA Vaccines Panel
Sponsor and agency sought to proactively address questions about the potential for anaphylactic reactions with the COVID-19 vaccine given the early real-world experience with Pfizer’s inoculation, which is also uses mRNA technology.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: